Global Connected Drug Delivery Devices Market

Connected Drug Delivery Devices Market Size, Share, Growth Analysis, By Product Type (Connected Inhalers, Metered Dose Inhalers (MDIs)), By Technology (Bluetooth, Wi-Fi), By Application (Diabetes, Insulin Delivery), By End-User, By Region - Industry Forecast 2026-2033

Report ID: SQMIG35G2246 | Region: Global | Published Date: November, 2025
Pages: 157 |Tables: 37 |Figures: 74

To request a free sample copy of this report, please complete the form below.

Our Clients

Schineder Electric

KSIA - Korea Semiconductor Industry Association

Hitachi Astemo Limited

Samsung Electronics

Halvo holdings

NTT corporation

AGC Inc

Siemens AG

Unilever

Merck Pharmaceuticals

Atlas Copco

Hologic - Medical Technology company

Novartis

Henkel

Reckitt

Schineder Electric

KSIA - Korea Semiconductor Industry Association

Hitachi Astemo Limited

Samsung Electronics

Halvo holdings

NTT corporation

AGC Inc

Siemens AG

Unilever

Merck Pharmaceuticals

Atlas Copco

Hologic - Medical Technology company

Novartis

Henkel

Reckitt

FAQs

Connected Drug Delivery Devices Market size was valued at USD 7.47 Billion in 2024 and is poised to grow from USD 9.29 Billion in 2025 to USD 52.92 Billion by 2033, growing at a CAGR of 24.3% during the forecast period (2026–2033).

The global connected drug delivery devices market is characterized by a mix of established companies and emerging players. Market participants are focusing on research and development activities to enhance the efficiency and performance of connected drug delivery devices. Additionally, strategic collaborations, partnerships, and mergers and acquisitions are prevalent strategies adopted by companies to expand their market presence. The competitive environment is further influenced by factors such as technological advancements, government regulations, and the ability to provide cost-effective and sustainable solutions. 'Findair Sp. z o. o. (Poland) ', 'BIO CORP (France) ', 'Teva Pharmaceuticals Industries Ltd (Israel) ', 'Adherium Limited (New Zealand) ', 'West Pharmaceutical Services Inc. (USA) ', 'Aptar Pharma (USA) ', 'Ypsomed AG (Switzerland) ', 'Phillips-Medisize (USA) ', 'H&T Presspart Manufacturing Ltd (UK) ', 'Cohero Health, Inc. (USA) ', '3M Company (USA) ', 'Becton, Dickinson and Company (USA) ', 'Merck KGaA (Germany) ', 'Novartis AG (Switzerland) ', 'Johnson & Johnson (USA) ', 'AstraZeneca (UK) ', 'GlaxoSmithKline plc (UK) ', 'Pfizer Inc. (USA) ', 'Sanofi S.A. (France) ', 'F. Hoffmann-La Roche Ltd (Switzerland) '

One key driver of the global connected drug delivery devices market is the increasing demand for personalized and connected healthcare solutions. Connected drug delivery devices offer several benefits such as remote patient monitoring, real-time data collection, and improved medication adherence. These devices enable healthcare providers to track patient health, adjust treatment plans, and provide personalized care. The integration of connected technologies with drug delivery devices also enhances patient engagement and improves treatment outcomes. Additionally, the growing prevalence of chronic diseases and the need for advanced drug delivery systems contribute to the market growth of connected drug delivery devices.

One key market trend in the global connected drug delivery devices market is the increasing adoption of smart inhalers and connected devices for respiratory therapies. These devices are equipped with sensors, wireless connectivity, and mobile applications to monitor and track patients' medication usage, dosage, and adherence. The integration of digital technologies in drug delivery devices enables real-time data collection, remote monitoring, and personalized treatment plans. This trend promotes patient engagement and empowerment by providing them with valuable insights and feedback on their medication usage.

One dominant region in the global connected drug delivery devices market is North America. With its advanced healthcare infrastructure, strong presence of key market players, and high adoption of connected healthcare technologies, North America has emerged as a leading region in the connected drug delivery devices market. The region has witnessed significant investments in research and development, technological advancements, and government initiatives to promote digital health solutions. The presence of major pharmaceutical companies and increasing collaborations between healthcare providers and technology companies further contribute to the dominance of North America in the market.

Connected Drug Delivery Devices Market Size, Share, Growth Analysis, By Product Type (Connected Inhalers, Metered Dose Inhalers (MDIs)), By Technology (Bluetooth, Wi-Fi), By Application (Diabetes, Insulin Delivery), By End-User, By Region - Industry Forecast 2026-2033

To request a free sample copy of this report, please complete the form below.

Our Clients

FAQs

What is the global market size of Connected Drug Delivery Devices Market?

Who are the key vendors in the Connected Drug Delivery Devices Market?

What is the key driver of Connected Drug Delivery Devices Market?

What is the key market trend for Connected Drug Delivery Devices Market?

Which region accounted for the largest share in Connected Drug Delivery Devices Market?

$5,300